MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Clinical trials for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can pressurized oxygen boost stem cell transplants?
Disease control Recruiting nowThis early-phase study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant preparation is safe and helps recovery. It involves 24 adults with various blood cancers, such as leukemia and myelofibrosis. Th…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: EARLY_PHASE1 • Sponsor: Omar Aljitawi • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune booster: personalized NK cells aim to wipe out blood cancer after transplant
Disease control Recruiting nowThis phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Immune cells armed to hunt down hidden leukemia
Disease control Recruiting nowThis early-phase trial tests a new cell therapy for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of cancer cells after standard treatment. The therapy uses the patient's own blood cells, armed with a special antibody to t…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for tough blood cancers: LP-118 trial launches
Disease control Recruiting nowThis early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New targeted drug shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new drug called BGB-11417 (sonrotoclax) in people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or related blood cancers. The drug works by blocking a protein that helps cancer cells survive. The trial will give the drug alone or toge…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo targets tough blood cancers
Disease control Recruiting nowThis phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo aims to boost transplant success in rare blood cancer
Disease control Recruiting nowThis study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug cocktail targets tough blood cancers
Disease control Recruiting nowThis study tests a combination of three drugs—ivosidenib, venetoclax, and azacitidine—in people with blood cancers like acute myeloid leukemia (AML) that have a specific IDH1 mutation. The goal is to see if the combo is safe and works better than current treatments. About 96 adul…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo aims to shrink Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new antibody called axatilimab, given with or without the chemotherapy drug azacitidine, for people with advanced myeloproliferative neoplasms (MPN), MPN/MDS overlap, or high-risk chronic myelomonocytic leukemia (CMML). The goal is to find the safest dose and s…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo aims to boost stem cell transplant success for tough blood cancers
Disease control Recruiting nowThis early-stage trial is testing whether adding two drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant can safely help control high-risk myeloid cancers like acute myeloid leukemia. About 20 adults aged 18-75 with a matched donor will receive …
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Could detoxing metals boost chemo for leukemia?
Disease control Recruiting nowThis early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo aims to tame Graft-Versus-Host disease in older blood cancer patients
Disease control Recruiting nowThis phase 2 trial tests whether adding the drug ruxolitinib to standard care can prevent graft-versus-host disease (GVHD) in older patients with myelofibrosis or MDS/MPN overlap syndromes who receive a donor stem cell transplant. About 50 participants will get ruxolitinib before…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Blood cancer bleeding breakthrough? TXA trial aims to cut hospitalizations
Symptom relief Recruiting nowThis study tests whether tranexamic acid (TXA), a drug that prevents blood clots from breaking down, can safely reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 outpatients receiving less-intensive chemotherapy will be rando…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Telehealth program aims to improve end-of-life conversations for older cancer patients
Knowledge-focused Recruiting nowThis study tests a telehealth program that helps older adults (60+) with blood cancers like leukemia or MDS talk to their doctors about their care wishes. The program also helps them fill out advance directive forms. Researchers want to see if it improves communication and reduce…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: NA • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC